Abstract
AbstractMajor depressive disorder (MDD) is associated with circadian rhythm disruption. Yet, no circadian rhythm biomarkers have been clinically validated for assessing antidepressant response. In this study, 40 participants with MDD provided actigraphy data using wearable devices for one week after initiating antidepressant treatment in a randomized, double-blind, placebo-controlled trial. Their depression severity was calculated pretreatment, after one week and eight weeks of treatment. This study assesses the relationship between parametric and nonparametric measures of circadian rhythm and change in depression. Results show significant association between a lower circadian quotient (reflecting less robust rhythmicity) and improvement in depression from baseline following first week of treatment (estimate = 0.11, F = 7.01, P = 0.01). There is insufficient evidence of an association between circadian rhythm measures acquired during the first week of treatment and outcomes after eight weeks of treatment. Despite this lack of association with future treatment outcome, this scalable, cost-effective biomarker may be useful for timely mental health care through remote monitoring of real-time changes in current depression.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics,Computer Science Applications,Medicine (miscellaneous)
Reference87 articles.
1. McCall, W. V. A rest-activity biomarker to predict response to SSRIs in major depressive disorder. J. Psychiatr. Res. 64, 19–22 (2015).
2. Battle, C. L. et al. Treatment goals of depressed outpatients: a qualitative investigation of goals identified by participants in a depression treatment trial. J. Psychiatr. Pr. 16, 425–430 (2010).
3. Reddy, M. S. Depression: the disorder and the burden. Indian J. Psychol. Med. 32, 1–2 (2010).
4. Goodwin, R. D. et al. Trends in U.S. depression prevalence from 2015 to 2020: the widening treatment gap. Am. J. Prevent. Med. 63, 726–733 (2022).
5. Lorenzo-Luaces, L., Rodriguez-Quintana, N. & Bailey, A. J. Double trouble: do symptom severity and duration interact to predicting treatment outcomes in adolescent depression? Behav. Res Ther. 131, 103637 (2020).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献